Near real‐time vaccine safety surveillance using electronic health records—a systematic review of the application of statistical methods

Pharmacoepidemiology and Drug Safety - Tập 25 Số 3 - Trang 225-237 - 2016
Andreia Leite1, Nick Andrews2, Sara L. Thomas1
1Faculty of Epidemiology and Population Health London School of Hygiene & Tropical Medicine London UK
2Statistics, Modelling and Economics Department, Public Health England, London, UK

Tóm tắt

AbstractPurposePre‐licensure studies have limited ability to detect rare adverse events (AEs) to vaccines, requiring timely post‐licensure studies. With the increasing availability of electronic health records (EHR) near real‐time vaccine safety surveillance using these data has emerged as an option. We reviewed methods currently used to inform development of similar systems for countries considering their introduction.MethodsMedline, EMBASE and Web of Science were searched, with additional searches of conference abstract books. Questionnaires were sent to organizations worldwide to ascertain unpublished studies. Eligible studies used EHR and regularly assessed pre‐specified AE to vaccine(s). Key features of studies were compared descriptively.ResultsFrom 2779 studies, 31 were included from the USA (23), UK (6), and Taiwan and New Zealand (1 each). These were published/conducted between May 2005 and April 2015. Thirty‐eight different vaccines were studied, focusing mainly on influenza (47.4%), especially 2009 H1N1 vaccines. Forty‐six analytic approaches were used, reflecting frequency of EHR updates and the AE studied. Poisson‐based maximized sequential probability ratio test was the most common (43.5%), followed by its binomial (23.9%) and conditional versions (10.9%). Thirty‐seven of 49 analyses (75.5%) mentioned control for confounding, using an adjusted expected rate (51.4% of those adjusting), stratification (16.2%) or a combination of a self‐controlled design and stratification (13.5%). Guillain‐Barré syndrome (11.9%), meningitis/encephalitis/myelitis (11.9%) and seizures (10.8%) were studied most often.ConclusionsNear real‐time vaccine safety surveillance using EHR has developed over the past decade but is not yet widely used. As more countries have access to EHR, it will be important that appropriate methods are selected, considering the data available and AE of interest. © 2016 The Authors. Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.

Từ khóa


Tài liệu tham khảo

10.1016/j.biologicals.2012.07.007

Chen RT, 2011, Pharmacoepidemiology, 423

10.1016/S1359-6446(04)03234-9

10.1016/S1538-5442(01)70025-9

10.1586/erv.10.20

Dal Pan GJ, 2011, Pharmacoepidemiology, 137

10.1586/14760584.2014.866895

10.1590/S0034-89102011000100020

10.1097/01.ede.0000155506.05636.a4

Kulldorff M., 2011, Pharmacoepidemiology, 852

10.1542/peds.2010-1722I

10.1177/0962280211413452

10.1097/MLR.0b013e3180616c0a

Brighton Collaboration.Newsletter.2015;.https://brightoncollaboration.org/public/newsletter.html(accessed 19 June 2015).

World Health Organization.The Global Advisory Committee on Vaccine Safety.2015;http://www.who.int/vaccine_safety/committee/en/(accessed 19 May 2015).

Brighton Collaboration.Who we are.2015;https://brightoncollaboration.org/public/who‐we‐are.html(accessed 19 May 2015).

ADVANCE.About ADVANCE.2015;http://www.advance‐vaccines.eu/(accessed 2015‐05‐19).

Government Digital Service.Medicines & Healthcare products Regulatory Agency.2015;https://www.gov.uk/government/organisations/medicines‐and‐healthcare‐products‐regulatory‐agency(accessed 19 May 2015).

Centers for Disease Control and Prevention.Vaccine Safety Datalink (VSD).2015;http://www.cdc.gov/vaccinesafety/Activities/VSD.html(accessed 19 May 2015).

Statens Serum Institut.Statens Serum Institut.2015;http://www.ssi.dk/english.aspx(accessed 19 May 2015).

10.4161/hv.3.5.4458

10.1097/MLR.0b013e3181b58b5c

10.1016/j.vaccine.2009.05.036

10.1093/aje/kwp345

10.1097/INF.0b013e3181af8605

National Vaccine Advisory Committee (NVAC).Report on 2009 H1N1 vaccine safety risk assessment. NVAC.2010;http://www.hhs.gov/nvpo/nvac/reports/vsrawg_report_apr2010.html(accessed 19 June 2015).

10.1542/peds.2010-0665

10.1016/S0140-6736(10)61221-4

Enger C, 2010, H1N1 influenza vaccine surveillance project, Pharmacoepidemiol Drug Saf, 19, S14

10.1016/j.vaccine.2010.08.069

10.1016/S0140-6736(11)60352-8

10.1542/peds.2010-1722L

10.1016/j.amepre.2011.04.004

10.1016/j.vaccine.2011.08.106

10.1097/INF.0b013e3182421390

10.2105/AJPH.2011.300510

10.1016/j.vaccine.2012.01.027

10.1093/aje/kws317

10.1016/j.vaccine.2013.03.040

10.1016/j.vaccine.2013.08.024

10.1056/NEJMoa1311738

10.1016/j.vaccine.2014.03.063

10.1002/pds.3575

10.1016/S0140-6736(14)62136-X

YihK ZichitellaL SandhuS NguyenM KuldorffM ColeD et al.Accessing the freshest feasible data for conducting active influenza vaccine safety surveillance. Mini‐Sentinel.2015;http://www.mini‐sentinel.org/work_products/PRISM/Mini‐Sentinel_PRISM_Active‐Influenza‐Vaccine‐Safety‐Surveillance‐Report.pdf(accessed 19 June 2015).

10.1002/pds.2133

GarmanP.Enhanced surveillance of novel H1N1 vaccines among military personnel. Defense Medical Surveillance System.2009;http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesBloodVaccinesandO/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM198078.ppt(accessed 19 June 2015) ND.

National Vaccine Advisory Committee (NVAC).H1N1 Vaccine Safety Risk Assessment Working Group Report. NVAC.2012;http://www.hhs.gov/nvpo/nvac/reports/vsrawg_report_january_2012.pdf(accessed 19 June 2015).

SandhuSK.Update on Surveillance for Guillain‐Barré Syndrome after Vaccination with Pandemic Influenza A/H1N1 2009‐containing Vaccines 2009–2011. Vaccines and Related Biological Products Advisory Committee.2011;http://fda.yorkcast.com/webcast/Viewer/?peid=75dcd91903204870aff160cb9d5528151d(accessed 19 June 2015).

10.1080/07474946.2011.539924

10.1002/sim.3780

Ellenberg SS, 2003, Data Monitoring Committees in Clinical Trials: A Practical Perspective, 119

10.1002/sam.11234

10.1002/(SICI)1521-4036(199804)40:1<21::AID-BIMJ21>3.0.CO;2-Z

10.1002/pds.2320

Carey RG, 2003, Improving Healthcare with Control Charts: Basic and Advanced SPC Methods and Case Studies

LewisE FiremanB KleinNP BaxterR.Exact sequential analysis for vaccine safety surveillance. 12th Annual Conference on Vaccine Research Bethesda;2009.http://www.nfid.org/professional‐education/archives/acvr/acvr09.pdf(accessed 19 June 2015).

10.1111/biom.12324

10.1201/9781584888581

10.1177/096228020301200205

10.1016/j.vaccine.2008.08.010

10.1111/rssc.12076

10.1002/sim.6398

10.1002/pds.3856

10.1002/pds.3618

10.1002/pds.2324

Kuldorff M, 2015, Continuous post‐market sequential safety surveillance with minimum events to signal, Rev Stat

10.1002/pst.1593

Thông tin
Thông tin xuất bản

Pharmacoepidemiology and Drug Safety

Tập 25 Số 3

225-237

Thông tin tác giả